POETYK LTE trial: 2 year follow-up of deucravacitinib in plaque psoriasis

Deucravacitinib, an oral TYK2 inhibitor, has shown promising survival results and a manageable safety profile in patients with moderate to severe plaque psoriasis in POETYK PSO-1 and PSO-2 clinical trials. Here, we summarize the latest follow-up data from the POETYK LTE trial published by Lebwohl M et al¹ in British Journal of Dermatology investigating long-term results and durability of deucravacitinib from the above two trials.

Study design

• POETYK LTE (NCT04036435) is a phase 3, ongoing extension trial (N=1519)
• The primary endpoint was safety assessed as exposure-adjusted incidence rates (EAIR) of adverse events (AE)
• Efficacy was measured as ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA)
• Mean age of patients was 46.6 years

Key findings

• EAIRs of AEs, serious adverse events and AEs resulting in treatment discontinuation were reported lower when assessed over 2 years compared with 1 year (Table 1)
• The most reported adverse events over the 2 year follow-up were:
  • Nasopharyngitis (12.9/100 person years (PY))
  • Upper respiratory tract infections (6.5/100 PY) and;
  • COVID-19 (5.1/PY)
• In total, 10 deaths were reported in the 2-year period and 6 related to COVID-19
  • Patients were not fully vaccinated from COVID-19 and were ≥50 years

 Table 1. Overall safety results in Year 1 compared with Year 2*

• Long-term deucravacitinib maintained or improved efficacy after Week 112 compared with start of the extension trial (Week 52):
  • PASI75: 79.7% vs 72.4%, respectively
  • PASI90: 51.5% vs 45.8%, respectively
  • sPGA 0/1: 61.1% vs 57.9%, respectively